Lupin completes successful Phase 3 trials for Lucentis biosimilar

The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU

Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar

Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance

Soumya Swaminathan appointed as the Principle Advisor for the National Tuberculosis Elimination Programme

Zydus and Dr. Reddy's announce licensing agreement for co?marketing of Pertuzumab biosimilar

Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States

Mankind Pharma launches 'Limit White India' campaign to raise hypertension awareness

Briefs: Sun Pharma and Kimia Biosciences

Sun Pharma's Dadra facility receives OAI status from US FDA

Pfizer and AIF’s Project Parivartan demonstrates progress in addressing antimicrobial resistance

Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms

Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024

CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab'

Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer